Who are we?

MiMIAT Health has developed a patient-controlled longitudinal health record that makes disease evolution visible and enables data continuity across fragmented care settings for multidisciplinary teams managing hard-to-diagnose diseases.

Our work has been recognised through PRECISEU Best Practice Recognition, AstraZeneca ACCIÓN, Google for Startups for Sustainable Development and NVIDIA Inception. We are also part of COST Action CA24114, focused on blood, tissues and cells as starting materials for advanced therapies.

Building on this foundation, MiMIAT is now establishing a biotech translational R&D arm focused initially on advanced therapies. We are assembling the scientific, clinical, regulatory, manufacturing and operational nucleus required to select promising research and advance an initial programme towards defined therapeutic-development milestones. The team and model are being shaped now, creating an opportunity for the right people to influence the initiative from its earliest stage.

What is this role about?

We are looking for an experienced Senior Translational Development Advisor who can help determine how this thesis could work in practice and convert it into a credible first operating model.

This is not a general advisory or networking role. We need someone who understands how cell, gene or tissue-based therapies progress from scientific research through preclinical development, where applicable, SoHO collection, CMC/GMP manufacturing, clinical studies and long-term patient follow-up.

The advisor will help us identify where MiMIAT can create meaningful and defensible value, what capabilities and partners would be required, and which initial use case offers the strongest route towards a funded pilot or co-development programme.

The intended outcome of the initial appointment is a clear blueprint showing what MiMIAT should pursue first, with whom, under which regulatory and operational conditions, and through which development milestones.

What you’ll do

• Critically assess MiMIAT’s current SoHO–ATMP thesis and identify its strongest assumptions, gaps and risks.
• Map a representative patient-to-therapy pathway covering patient involvement, SoHO collection, processing or manufacturing, clinical administration and longitudinal follow-up.
• Help define MiMIAT’s precise role across the patient, biological-product and clinical-evidence pathways—including which responsibilities must remain with hospitals, SoHO establishments, clinical sponsors, laboratories and GMP manufacturers.
• Identify and prioritise the most credible initial use case for MiMIAT, such as patient engagement, longitudinal outcomes, clinical-outcome monitoring or patient-evidence coordination around an advanced-therapy programme.
• Develop selection criteria for potential therapeutic programmes, considering scientific validity, clinical relevance, regulatory feasibility, manufacturing requirements, intellectual property and commercial potential.
• Identify the key stakeholders required for the first programme, including academic investigators, clinical sites, SoHO establishments, CDMOs or GMP facilities, regulatory experts, patient organisations and potential pharma or licensing partners.
• Assess which parts of MiMIAT’s current platform could support this model and which additional integrations, validation, governance or product capabilities would be required.
• Help structure an initial partner proposition and pilot blueprint, including responsibilities, milestones, evidence requirements, indicative resources and go/no-go decisions.
• Highlight where additional scientific, clinical, regulatory, quality, manufacturing, legal or data expertise must be brought into the initiative.

This role does not involve performing laboratory research, assuming clinical responsibility, providing formal regulatory sign-off or acting as the sponsor or manufacturer of an ATMP.

Who are you?

• You have at least 5 years of relevant experience in advanced therapies, translational medicine or a closely related regulated field.
• You hold an MSc, PhD, PharmD, MD or equivalent qualification in biotechnology, biomedical sciences, cell or molecular biology, genetics, immunology, regenerative medicine, tissue engineering, pharmaceutical sciences, medicine, bioengineering or bioprocess engineering.
• You have worked in biotech, pharma, a hospital advanced-therapies unit, SoHO establishment, translational research centre, GMP facility, CDMO, CRO or relevant regulatory environment.
• You have directly supported at least one cell, gene or tissue-based programme and helped move it between development stages.
• You understand several areas across translational science, SoHO/ATMP classification, CMC, GMP, clinical development, quality, patient follow-up or evidence generation.
• You can turn complex scientific and regulatory dependencies into clear priorities, stakeholder responsibilities and actionable next steps.
• You are comfortable challenging an early-stage thesis rather than simply validating what we already believe.

Experience with Regulation (EU) 2024/1938, EMA/CAT, AEMPS, academic technology transfer, clinical-outcome monitoring or European research consortia is especially valuable.

Engagement and future possibilities

• This is an initial six-week unpaid advisory engagement requiring approximately 2–3 hours per week.
• You will work directly with the Founder & CEO to help shape MiMIAT’s emerging biotech model, validate its first advanced-therapy thesis and translate the vision into a credible development pathway.
• At the end of the six weeks, if there is a strong mutual fit and the initiative has progressed sufficiently, we may explore a continuing role as a programme lead, implementation or operating contributor, ongoing advisor or, where the alignment and commitment justify it, a member of the founding team behind the new structure. Any continuation (including responsibilities, time commitment, compensation and any potential equity) would be negotiated separately and documented in a formal written agreement.
• This exploratory engagement does not itself guarantee or create an entitlement to any future role, compensation, equity or appointment.
• You will have the opportunity to shape an emerging biotech model at the intersection of advanced therapies, patient-centred data and translational development.

How to apply

Send your CV to info@mimiathealth.com or reach out directly here on LinkedIn.

Please include a brief description of the most relevant advanced-therapy programme you have supported, the development stage involved and the responsibility you personally held.

And if this speaks to you, we’d love to hear from you!